{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:08:17Z","timestamp":1790071697443,"version":"4.0.1"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Antibiotics account for more cases of idiosyncratic drug-induced liver injury (DILI) than any other drug class. At the bedside, attributing injury to a particular antibiotic is difficult: there is no confirmatory test, and latency and biochemical pattern vary markedly among agents. Spontaneous-reporting databases add a second kind of evidence. Disproportionality analyses repeatedly identify strong reporting signals for amoxicillin-clavulanate and nitrofurantoin, but these describe reporting patterns rather than incidence, rest on reports that are seldom assessed by a validated causality method, and cannot establish causation in an individual patient. This review considers how clinical pharmacists might use such population-level information, together with the globally used updated Roussel Uclaf Causality Assessment Method (RUCAM), without overstating what either can show. We bring together evidence on culprit antibiotics and their characteristic phenotypes, the mechanistic basis of susceptibility markers including HLA-B*57:01 and slow NAT2 acetylator status, the methods and limits of disproportionality analysis, and the pharmacist\u2019s role in medication review and monitoring. On that basis we propose a closed surveillance cycle. A pharmacovigilance signal first informs risk stratification and the timing of laboratory monitoring; suspected cases then undergo updated RUCAM assessment, which yields a quantitative causality score at no marginal cost, with genotyping reserved for patients in whom the result would change interpretation; intervention and structured reporting close the loop. Published antibiotic-associated cases are tabulated with their RUCAM scores and susceptibility results. Research priorities include prospective validation of composite risk scores, agreed monitoring intervals, multicenter evaluation of pharmacist-led detection, and appraisal of emerging biomarkers.<\/jats:p>","DOI":"10.3389\/fphar.2026.1956601","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:39:27Z","timestamp":1790069967000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A pharmacist-led framework for antibiotic-associated liver injury: from pharmacovigilance signals to bedside surveillance with the updated RUCAM and susceptibility markers"],"prefix":"10.3389","volume":"17","author":[{"given":"Chao","family":"Liu","sequence":"first","affiliation":[{"name":"Zigong First People\u2019s Hospital","place":["Zigong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[{"name":"Zigong First People\u2019s Hospital","place":["Zigong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"Lin","sequence":"additional","affiliation":[{"name":"Zigong First People\u2019s Hospital","place":["Zigong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40264-025-01603-z","article-title":"R value-based criteria outperform alkaline phosphatase less than twice normal in identifying Hy's law cases in clinical trials","volume":"49","author":"Amirzadegan","year":"2026","journal-title":"Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/liv.14271","article-title":"Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice","volume":"40","author":"Andrade","year":"2020","journal-title":"Liver Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/jac\/dkr159","article-title":"Hepatic safety of antibiotics used in primary care","volume":"66","author":"Andrade","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/j.gastro.2005.05.006","article-title":"Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.tox.2008.08.009","article-title":"Flucloxacillin-induced liver injury","volume":"254","author":"Andrews","year":"2008","journal-title":"Toxicology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1080\/17425255.2021.1999410","article-title":"Biomarkers of idiosyncratic drug-induced liver injury: a systematic review","volume":"17","author":"Atallah","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.22037\/ijpr.2014.1442","article-title":"Increasing the number of adverse drug reactions reporting: the role of clinical pharmacy residents","volume":"13","author":"Baniasadi","year":"2014","journal-title":"Iran. J. Pharm. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/ijms17030313","article-title":"The Latin American DILI registry experience: a successful ongoing collaborative strategic initiative","volume":"17","author":"Bessone","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00204-022-03419-7","article-title":"Nitrofurantoin-induced liver injury: long-term follow-up of two prospective DILI registries","volume":"97","author":"Bessone","year":"2023","journal-title":"Arch. Toxicol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/ijms17020224","article-title":"Hepatotoxicity by drugs: the most common implicated agents","volume":"17","author":"Bj\u00f6rnsson","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bj\u00f6rnsson","year":"2013","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/liv.15378","article-title":"The prospective European DILI registry: 12-year outcomes in patients with drug-induced liver injury","volume":"43","author":"Bj\u00f6rnsson","year":"2023","journal-title":"Liver Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/jgh.12516","article-title":"Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress","volume":"29","author":"Boelsterli","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e47769","DOI":"10.1371\/journal.pone.0047769","article-title":"Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis","volume":"7","author":"Cai","year":"2012","journal-title":"PLoS One"},{"key":"B17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3390\/jpm12050790","article-title":"Clinical and genetic risk factors for drug-induced liver injury associated with anti-tuberculosis treatment: a study from patients of Portuguese health centers","volume":"12","author":"Cavaco","year":"2022","journal-title":"J. Pers. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","article-title":"DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans","volume":"21","author":"Chen","year":"2016","journal-title":"Drug Discov. Today"},{"key":"B21","doi-asserted-by":"publisher","first-page":"813682","DOI":"10.3389\/fphar.2022.813682","article-title":"Prophylactic hepatoprotective agents for anti-tuberculosis drug-induced liver injury: a network meta-analysis","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1021\/acs.chemrestox.6b00357","article-title":"How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic drug reaction","volume":"30","author":"Cho","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/hep.29802","article-title":"Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort","volume":"69","author":"Church","year":"2019","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1080\/17425255.2025.2577677","article-title":"Modifying Hy's law and eDISH for the modern idiosyncratic DILI era","volume":"21","author":"Cohen","year":"2025","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat. Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3389\/fphar.2019.00853","article-title":"Drug-induced liver injury: why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch?","volume":"10","author":"Danan","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e18322","DOI":"10.1097\/MD.0000000000018322","article-title":"Novel biomarkers for risk stratification in drug-induced liver injury: a narrative review","volume":"98","author":"Danjuma","year":"2019","journal-title":"Med. Baltim."},{"key":"B29","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12877-020-01732-3","article-title":"Avoidability of drug-induced liver injury (DILI) in an elderly hospital cohort with cases assessed for causality by the updated RUCAM score","volume":"20","author":"Danjuma","year":"2020","journal-title":"BMC Geriatr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1007\/s10620-016-4121-6","article-title":"Amoxicillin\u2013Clavulanate-induced liver injury","volume":"61","author":"deLemos","year":"2016","journal-title":"Amoxicillin-clavulanate-induced Liver Injury. Dig. Dis. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF00192363","article-title":"Flucloxacillin associated cholestatic hepatitis: an Australian and Swedish epidemic?","volume":"49","author":"Devereaux","year":"1995","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e50151","DOI":"10.7759\/cureus.50151","article-title":"The role of clinical pharmacists in antimicrobial stewardship programs: a systematic review","volume":"15","author":"Dighriri","year":"2023","journal-title":"Cureus"},{"key":"B33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1472-6963-7-54","article-title":"ALFIE decision support for managing abnormal liver function test results in primary care","volume":"7","author":"Donnan","year":"2007","journal-title":"BMC Health Serv. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct","volume":"32","author":"Fontana","year":"2009","journal-title":"Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2014.03.045","article-title":"Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset","volume":"147","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1016\/j.cgh.2022.12.040","article-title":"The evolving profile of idiosyncratic drug-induced liver injury","volume":"21","author":"Fontana","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1097\/HEP.0000000000000583","article-title":"Clinical decision support in chronic liver disease: a national multicenter study","volume":"81","author":"Ge","year":"2025","journal-title":"Hepatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1309\/KV2J-VX6Q-L95V-VDE4","article-title":"Minocycline as a cause of drug-induced autoimmune hepatitis: report of four cases and comparison with autoimmune hepatitis","volume":"114","author":"Goldstein","year":"2000","journal-title":"Am. J. Clin. Pathol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/cpt.2930","article-title":"Drug-induced liver injury with commonly used antibiotics in the all of us research program","volume":"114","author":"Gu","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5223\/pghn.2018.21.4.347","article-title":"Minocycline-induced autoimmune hepatitis: a rare but important cause of drug-induced autoimmune hepatitis","volume":"21","author":"Harmon","year":"2018","journal-title":"Pediatr. Gastroenterol. Hepatol. Nutr."},{"key":"B42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/hep.32327","article-title":"A revised electronic version of RUCAM for the diagnosis of drug-induced liver injury","volume":"76","author":"Hayashi","year":"2022","journal-title":"Hepatology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"40579","DOI":"10.1038\/s41598-025-24262-7","article-title":"Identifying high-risk drugs and demographic patterns in drug-induced liver injury from FAERS and CVARD analyses","volume":"15","author":"He","year":"2025","journal-title":"Sci. Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/hep.26175","article-title":"LiverTox: a website on drug-induced liver injury","volume":"57","author":"Hoofnagle","year":"2013","journal-title":"Hepatology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"17562848231163410","DOI":"10.1177\/17562848231163410","article-title":"Drug-induced liver injury: a comprehensive review","volume":"16","author":"Hosack","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e73133","DOI":"10.1371\/journal.pone.0073133","article-title":"Circulating microRNA-122 is a biomarker of cholestatic drug-induced liver injury","volume":"8","author":"Huang","year":"2013","journal-title":"PLoS One"},{"key":"B47","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/15563650.2023.2259089","article-title":"Novel biomarkers for the identification and management of drug-induced liver injury","volume":"61","author":"Humphries","year":"2023","journal-title":"Clin. Toxicol. (Phila)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.3390\/ijms22062954","article-title":"Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges","volume":"22","author":"Jee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"525","DOI":"10.5694\/j.1326-5377.1994.tb138327.x","article-title":"Flucloxacillin and cholestatic hepatitis","volume":"160","author":"Jick","year":"1994","journal-title":"Med. J. Aust."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1772312","DOI":"10.3389\/fpubh.2026.1772312","article-title":"Cost-utility analysis of stratified isoniazid dosing by NAT2 genotype compared with isoniazid standard regimen for new patients with pulmonary tuberculosis in Thailand","volume":"14","author":"Kantared","year":"2026","journal-title":"Front. Public Health"},{"key":"B51","doi-asserted-by":"publisher","first-page":"BSR20180845","DOI":"10.1042\/BSR20180845","article-title":"Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence","volume":"39","author":"Khan","year":"2019","journal-title":"Biosci. Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1186\/s12913-022-08320-8","article-title":"Effect of pharmacist-led intervention on adverse drug reaction reporting: a 9-year interrupted time series analysis","volume":"22","author":"Lan","year":"2022","journal-title":"BMC Health Serv. Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"972800","DOI":"10.3389\/fphar.2022.972800","article-title":"Impact of pharmacist active consultation on clinical outcomes and quality of medical care in drug-induced liver injury inpatients in general hospital wards: a retrospective cohort study","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B54","article-title":"Tetracyclines","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases","year":"2026"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e93434","DOI":"10.7759\/cureus.93434","article-title":"From therapy to toxicity: a rare case of acute piperacillin\/tazobactam-associated drug-induced liver injury","volume":"17","author":"Maheshwari","year":"2025","journal-title":"Cureus"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1021\/acs.chemrestox.5b00137","article-title":"The role of CD8 T cells in amodiaquine-induced liver injury in PD1-\/- mice cotreated with anti-CTLA-4","volume":"28","author":"Mak","year":"2015","journal-title":"Chem. Res. Toxicol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12072-023-10633-7","article-title":"Chinese clinical practice guidelines for the management of drug-induced liver injury","volume":"18","author":"Mao","year":"2024","journal-title":"Hepatol. Int."},{"key":"B58","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cgh.2014.07.054","article-title":"Clinical and histologic features of azithromycin-induced liver injury","volume":"13","author":"Mart\u00ednez","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/hep.26077","article-title":"Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury","volume":"57","author":"Monshi","year":"2013","journal-title":"Hepatology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"S2885","DOI":"10.1093\/ajhp\/zxae327","article-title":"Evaluation of a clinical decision support alert to identify hepatic dysfunction and need for medication therapy adjustment in hospitalized patients","volume":"82","author":"Nguyen","year":"2025","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e3827","DOI":"10.4212\/cjhp.3827","article-title":"Pharmacist-led assessment of drug-induced liver injury in hospitalized patients","volume":"78","author":"Ortiz","year":"2025","journal-title":"Can. J. Hosp. Pharm."},{"key":"B62","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.mcna.2018.05.009","article-title":"Role of the pharmacist in antimicrobial stewardship","volume":"102","author":"Parente","year":"2018","journal-title":"Med. Clin. North Am."},{"key":"B63","doi-asserted-by":"publisher","first-page":"642","DOI":"10.21037\/atm-20-5144","article-title":"Prevalence and clinical characteristics of antibiotics-associated drug-induced liver injury","volume":"9","author":"Park","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/hep.20081","article-title":"Hy's law","volume":"39","author":"Reuben","year":"2004","journal-title":"Hepatology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury","volume":"147","author":"Robles-D\u00edaz","year":"2014","journal-title":"Gastroenterology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1177\/10781552211019453","article-title":"Clinical decision support system for dose adjustment of anticancer drugs in patients with renal or hepatic impairment","volume":"28","author":"Rolvink","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B67","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B68","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1111\/bcp.14736","article-title":"Circulating microRNA-122 and keratin-18 as biomarkers for tuberculosis treatment-associated liver injury","volume":"87","author":"Rupprechter","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2125.2005.02370.x","article-title":"Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK general practice research database","volume":"60","author":"Russmann","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.2174\/092986709788803097","article-title":"Current concepts of mechanisms in drug-induced hepatotoxicity","volume":"16","author":"Russmann","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e73021","DOI":"10.1002\/ccr3.73021","article-title":"Acute drug-induced liver injury after four doses of nitrofurantoin, as evaluated for causality using the updated RUCAM, with a disproportionate rise in AST: a novel case report","volume":"14","author":"Sampat","year":"2026","journal-title":"Clin. Case Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/toxsci\/kfae031","article-title":"Cytokeratin-18 as a marker of drug-induced hepatocellular injury at therapeutic exposures in the paracetamol-before-prescription (PATH-BP) substudy","volume":"199","author":"Scullion","year":"2024","journal-title":"Toxicol. Sci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"ofaf695","DOI":"10.1093\/ofid\/ofaf695.2136","article-title":"Hepatotoxicity signals associated with commonly prescribed oral antibiotics: insights from the FAERS database [poster P-1969]","volume":"13","author":"Sebastian","year":"2026","journal-title":"Open Forum Infect. Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","article-title":"Incidence and etiology of drug-induced liver injury in mainland China","volume":"156","author":"Shen","year":"2019","journal-title":"Gastroenterology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e103145","DOI":"10.7759\/cureus.103145","article-title":"Drug-induced cholestasis secondary to meropenem in an elderly patient: report of a rare case","volume":"18","author":"Shrestha","year":"2026","journal-title":"Cureus"},{"key":"B76","doi-asserted-by":"publisher","first-page":"106301","DOI":"10.1016\/j.jinf.2024.106301","article-title":"Occurrence and predictors of laboratory abnormalities during outpatient parenteral antimicrobial therapy: a multicenter cohort study to inform laboratory test monitoring","volume":"89","author":"Stoorvogel","year":"2024","journal-title":"J. Infect."},{"key":"B77","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/FPC.0000000000000339","article-title":"NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis","volume":"28","author":"Suvichapanich","year":"2018","journal-title":"Pharmacogenet. Genomics"},{"key":"B78","doi-asserted-by":"publisher","first-page":"17301","DOI":"10.1038\/s41598-025-02359-3","article-title":"A disproportionality analysis of adverse events associated with ertapenem using the FAERS database from 2004 to 2024","volume":"15","author":"Tang","year":"2025","journal-title":"Sci. Rep."},{"key":"B79","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1590\/1806-9282.66.1.12","article-title":"Flucloxacillin-induced hepatotoxicity: association with HLA-B*5701","volume":"66","author":"Teixeira","year":"2020","journal-title":"Rev. Assoc. Med. Bras."},{"key":"B80","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol","volume":"15","author":"Temple","year":"2006","journal-title":"Drug Saf."},{"key":"B81","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2019.00730","article-title":"Idiosyncratic DILI: analysis of 46,266 cases assessed for causality by RUCAM and published from 2014 to early 2019","volume":"10","author":"Teschke","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.3390\/biomedicines12102208","article-title":"Idiosyncratic hepatocellular drug-induced liver injury by flucloxacillin with evidence based on Roussel Uclaf Causality Assessment Method and HLA B*57:01 genotype: from metabolic CYP 3A4\/3A7 to immune mechanisms","volume":"12","author":"Teschke","year":"2024","journal-title":"Biomedicines"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1771858","DOI":"10.3389\/fimmu.2026.1771858","article-title":"RUCAM-ascertained immunology and autoimmunity specifics of six idiosyncratic drug-induced liver injury types with refined classification: their individual complex molecular interplay","volume":"17","author":"Teschke","year":"2026","journal-title":"Front. Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/medicines7100062","article-title":"Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993-mid 2020: a comprehensive analysis","volume":"7","author":"Teschke","year":"2020","journal-title":"Medicines"},{"key":"B85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/medicines11040009","article-title":"Human leucocyte antigen genetics in idiosyncratic drug-induced liver injury with evidence based on the Roussel Uclaf Causality Assessment Method","volume":"11","author":"Teschke","year":"2024","journal-title":"Medicines"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3390\/diagnostics15131588","article-title":"Drug-induced autoimmune hepatitis: robust causality assessment using two different validated and scoring diagnostic algorithms","volume":"15","author":"Teschke","year":"2025","journal-title":"Diagnostics"},{"key":"B87","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/liv.12322","article-title":"Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts","volume":"34","author":"Thulin","year":"2014","journal-title":"Liver Int."},{"key":"B88","doi-asserted-by":"publisher","first-page":"101976","DOI":"10.1016\/j.toxrep.2025.101976","article-title":"Insights into medication-induced liver injury: understanding and management strategies","volume":"14","author":"Tiwari","year":"2025","journal-title":"Toxicol. Rep."},{"key":"B89","volume-title":"Fee Schedule Effective January 1, 2022","year":"2022"},{"key":"B90","volume-title":"Rates and CPT Codes 2020 (CMS #05-HL06)","year":"2020"},{"key":"B91","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/bs.apha.2018.12.001","article-title":"Mechanistic studies of idiosyncratic DILI: clinical implications","volume":"85","author":"Uetrecht","year":"2019","journal-title":"Adv. Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1124\/pr.113.007450","article-title":"Idiosyncratic adverse drug reactions: current concepts","volume":"65","author":"Uetrecht","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"B93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Drug Saf."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1128\/AAC.03122-15","article-title":"Adverse events lead to drug discontinuation more commonly among patients who receive nafcillin than among those who receive oxacillin","volume":"60","author":"Viehman","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B95","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/toxsci\/kfaa124","article-title":"Identification of flucloxacillin-haptenated HLA-B*57:01 ligands: evidence of antigen processing and presentation","volume":"177","author":"Waddington","year":"2020","journal-title":"Toxicol. Sci."},{"key":"B96","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/pds.1002","article-title":"The reporting odds ratio versus the proportional reporting ratio: 'deuce'. Pharmacoepidemiol","volume":"13","author":"Waller","year":"2004","journal-title":"Drug Saf."},{"key":"B97","doi-asserted-by":"publisher","first-page":"589","DOI":"10.5588\/ijtld.11.0377","article-title":"NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis","volume":"16","author":"Wang","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/jcpt.12388","article-title":"Updated meta-analysis of CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity","volume":"41","author":"Wang","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e027940","DOI":"10.1136\/bmjopen-2018-027940","article-title":"Genetic polymorphisms and anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis","volume":"9","author":"Yang","year":"2019","journal-title":"BMJ Open"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1564124","DOI":"10.3389\/fphar.2025.1564124","article-title":"The role of endoplasmic reticulum aminopeptidase ERAP2 pathogenic mutation rs1363907 in amoxicillin clavulanate-induced liver injury: a special case report","volume":"16","author":"Zhan","year":"2025","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1956601\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:39:29Z","timestamp":1790069969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1956601\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":100,"alternative-id":["10.3389\/fphar.2026.1956601"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1956601","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1956601"}}